NCT01615900
Completed
Not Applicable
Randomized Open Label Study Evaluating the Coverage by Teleconsultation Versus Standard Follow-up of Renal Transplant Patients According to a Risk Score of Early Graft Failure (KTFS)
ConditionsRenal Transplant Patient
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Renal Transplant Patient
- Sponsor
- Nantes University Hospital
- Enrollment
- 155
- Locations
- 1
- Primary Endpoint
- Number of serious adverse events
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
The main objective of this study is to optimize the coverage of renal transplant patients thanks to a personalized follow-up based on a risk score of early graft failure (KTFS, Kidney Transplant Failure Score), associated with teleconsultations.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult patient
- •Having received a deceased donor renal transplant one year ago
- •Having an access internet high-speed
- •Having a compatible computer and supporting the videoconference
- •Calculable KTFS (Kidney Transplant Failure Score)
- •Patient having participated in a therapeutic educational program
- •Patient has given informed consent
- •Patient insured
Exclusion Criteria
- •Patient under age 18
- •Patient having received a multi-organ transplant (heart kidney / liver kidney / kidney pancreas / lung kidney / heart lung kidney)
- •Patient non-compliant
- •BK virus nephropathy or BK positive viremia
- •CMV positive viremia
- •Identified and treated psychiatric disorders
- •Participation in another clinical study
- •Pregnancy
Outcomes
Primary Outcomes
Number of serious adverse events
Time Frame: 2 years
The main objective of this study is to optimize the coverage of renal transplant patients thanks to a personalized follow-up based on a risk score of early graft failure (KTFS, Kidney Transplant Failure Score), associated with teleconsultations.
Secondary Outcomes
- Cost-effectiveness of the personalized follow-up(2 years)
- Quality of life linked to the health of transplant patients(2 years)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
Study Comparing Sirolimus/Prograf vs Sirolimus/CsA in High-Risk Renal Transplant RecipientsRenal Allograft RecipientsNCT00470665Wyeth is now a wholly owned subsidiary of Pfizer460
Completed
Phase 3
Study Evaluating Sirolimus in Kidney Transplant RecipientsGraft vs Host DiseaseKidney TransplantationNCT00195273Wyeth is now a wholly owned subsidiary of Pfizer61
Completed
Phase 4
Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant RecipientsKidney TransplantationNCT00170885Novartis
Terminated
Phase 4
ATG Versus Basiliximab in Kidney Transplant Displaying Low Immunological Risk But High Susceptibility to DGFKidney TransplantationNCT02056938Nantes University Hospital19
Completed
Phase 4
A One-year, Open Label Study to Investigate the Safety and the Effect of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion in de Novo Kidney Transplant Recipients.Kidney TransplantationNCT00154245Novartis20